Kava, a tonic for relieving the irrational development of natural preventive agents

Cancer Prevention Research

Volumn 1, Issue 6, 2008, Pages 409-412

  Agarwal, Rajesh ^a   Deep, Gagan ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; KAVA; PLANT EXTRACT;

ANIMAL; BEVERAGE; CHEMISTRY; CHEMOPROPHYLAXIS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METHODOLOGY; MOUSE; NEOPLASM; NOTE; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVERAGES; BIOLOGICAL PRODUCTS; CHEMOPREVENTION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAVA; MICE; MICE, TRANSGENIC; NEOPLASMS; PLANT EXTRACTS;

EID: 61749086551     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0172     Document Type: Review

References (33)

1. Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin 2004;54:150-80.
2. Naithani R, Huma LC, Moriarty RM, McCormick DL, Mehta RG. Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr Med Chem 2008;15:1044-71.
3. Thomasset SC, Berry DP, Garcea G, Marczylo T, Steward WP, Gescher AJ. Dietary polyphenolic phytochemicals-promising cancer chemopreventive agents in humans? A review of their clinical properties. Int J Cancer 2007;120:451-8.
4. Szabo E. Assessing efficacy in early-phase cancer prevention trials: the case of oral premalignancy. Cancer Prev Res 2008;1:312-5.
5. Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 2001;15:465-89.
6. Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB. Anticancer potential of silymarin: from bench to bed side. Anticancer Res 2006; 26:4457-98.
7. Deep G, Agarwal R. Chemopreventive efficacy of silymarin in skin and prostate cancer. Integr Cancer Ther 2007;6:130-45.
8. Lahiri-Chatterjee M, Katiyar SK, Mohan RR, Agarwal R. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res 1999;59: 622-32.
9. Singh RP, Agarwal R. Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer 2006;13:751-78.
10. Velmurugan B, Singh RP, Tyagi A, Agarwal R. Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male Fisher 344 rats. Cancer Prev Res 2008;1:376-84.
11. Agarwal R. Cell signaling and regulators of cellcycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 2000;60:1051-9.
12. Qi L, Singh RP, Lu Y, et al. Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line. Cancer Biol Ther 2003;2: 526-31.
13. Petrelli A, Giordano S. From single- to multitarget drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008;15: 422-32.
14. Lee HY, Oh SH, Woo JK, et al. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst 2005;97:1695-9.
15. Oh SH, Woo JK, Yazici YD, et al. Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst 2007;99: 949-61.
16. Fang N, Casida JE. Anticancer action of cube insecticide: correlation for rotenoid constituents between inhibition of NADH:ubiquinone oxidoreductase and induced ornithine decarboxylase activities. Proc Natl Acad Sci U S A 1998;95: 3380-4.
17. Johnson TE, Kassie F, O'Sullivan MG, et al. Chemopreventive effect of kava on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo(a) pyreneinduced lung tumorigenesis in A/J mice. Cancer Prev Res 2008;1:430-8.
18. Tang Y, Simoneau AR, Xie J, Shahandeh B, Zi X. Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53. Cancer Prev Res 2008;1:439-51.
19. O'Sullivan HM, Lum K. The poisoning of 'awa: the non-traditional use of an ancient remedy. Pac Health Dialog 2004;11:211-5.
20. Tabudravu JN, Jaspars M. Anticancer activities of constituents of kava (Piper methysticum). The South Pac J Natural Sci 2005;23:26-9.
21. Clouatre DL. Kava kava: examining new reports of toxicity. Toxicol Lett 2004;150:85-96.
22. Henderson BE, Kolonel LN, Dworsky R, et al. Cancer incidence in the islands of the Pacific. Natl Cancer Inst Monogr 1985;69:73-81.
23. Steiner GG. The correlation between cancer incidence and kava consumption. Hawaii Med J 2000; 59:420-2.
24. Singh YN. Kava: an overview. J Ethnopharmacol 1992;37:13-45.
25. Weiss J, Sauer A, Frank A, Unger M. Extracts and kavalactones of Piper methysticum G. Forst (kavakava) inhibit P-glycoprotein in vitro. Drug Metab Dispos 2005;33:1580-3.
26. Zi X, Simoneau AR, Flavokawain A. A novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax proteindependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res 2005;65:3479-86.
27. Mitra AP, Birkhahn M, Cote RJ. p53 and retinoblastoma pathways in bladder cancer. World J Urol 2007;25:563-71.
28. Naugler WE, Karin M. NF-κB and cancer - identifying targets and mechanisms. Curr Opin Genet Dev 2008;18:19-26.
29. Deep G, Agarwal R. New combination therapies with cell-cycle agents. Curr Opin Investig Drugs 2008;9:591-604.
30. Dalton WB, Nandan MO, Moore RT, Yang VW. Human cancer cells commonly acquire DNA damage during mitotic arrest. Cancer Res 2007;67: 11487-92.
31. Whittaker P, Clarke JJ, San RH, et al. Evaluation of commercial kava extracts and kavalactone standards for mutagenicity and toxicity using the mammalian cell gene mutation assay in L5178Y mouse lymphoma cells. Food Chem Toxicol 2008;46:168-74.
32. Whitton PA, Lau A, Salisbury A, Whitehouse J, Evans CS. Kava lactones and the kava-kava controversy. Phytochemistry 2003;64:673-9.
33. Moulds RF, Malani J. Kava: herbal panacea or liver poison?. Med J Aust 2003;178:451-3.